Janux Therapeutics Ownership | Who Owns Janux Therapeutics?


OverviewForecastRevenueFinancialsChart

Janux Therapeutics Ownership Summary


Janux Therapeutics is owned by 5.58% institutional investors, 6.59% insiders, and 87.83% retail investors. Ra capital management is the largest institutional shareholder, holding 18.11% of JANX shares. Fidelity Growth Compy Commingled Pl S is the top mutual fund, with 3.72% of its assets in Janux Therapeutics shares.

JANX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockJanux Therapeutics5.58%6.59%87.83%
SectorHealthcare Stocks 279.18%10.62%-189.80%
IndustryBiotech Stocks 63.96%10.74%25.30%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ra capital management11.19M18.11%$302.12M
Fmr8.67M15.87%$464.19M
Janus henderson group3.56M6.52%$190.62M
Adage capital partners gp3.06M5.60%$163.93M
Paradigm biocapital advisors lp3.33M5.39%$89.91M
Blackrock funding, inc. /de2.73M4.99%$145.94M
Blackrock2.34M4.78%$98.19M
Vanguard group2.14M3.91%$114.38M
Woodline partners lp1.85M3.39%$99.17M
Cormorant asset management, lp2.00M3.24%$54.00M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Logos global management lp1.25M7.83%$66.92M
Prosight management, lp689.90K6.12%$18.63M
Ra capital management11.19M5.05%$302.12M
Ally bridge group (ny)90.29K4.14%$4.83M
Paradigm biocapital advisors lp3.33M4.12%$89.91M
Cormorant asset management, lp2.00M4.06%$54.00M
Avidity partners management lp741.90K3.90%$39.72M
Ecor1 capital1.47M2.98%$78.69M
Stempoint capital lp342.06K2.94%$9.24M
Bioimpact capital567.19K2.63%$15.31M

Top Buyers

HolderShares% AssetsChange
Janus henderson group3.56M0.10%1.04M
Holocene advisors, lp1.02M0.17%1.02M
State street1.40M0.00%1.00M
Adage capital partners gp3.06M0.29%986.75K
Price t rowe associates inc /md/1.11M0.01%950.56K

Top Sellers

HolderShares% AssetsChange
Rtw investments, lp---1.00M
Driehaus capital management---515.65K
Vestal point capital, lp---485.00K
Bvf inc/il---441.53K
Samlyn capital---324.70K

New Positions

HolderShares% AssetsChangeValue
Holocene advisors, lp1.02M0.17%1.02M$54.35M
Pictet asset management sa384.80K0.02%384.80K$20.60M
Rock springs capital management lp204.47K0.42%204.47K$10.95M
Tudor investment corp et al174.35K0.02%174.35K$4.71M
First trust advisors lp128.06K0.01%128.06K$6.86M

Sold Out

HolderChange
Quantbot technologies lp-1.00
National bank of canada /fi/-1.00
Corecap advisors-9.00
Capital performance advisors llp-17.00
Abich financial wealth management-20.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 20257-96.93%3,447,727-94.63%50.04%5-96.82%1-97.73%
Dec 31, 202421329.09%61,331,55034.45%1121.61%14967.42%37-22.92%
Sep 30, 20241642.50%45,609,3962.07%831.24%88-20.00%4845.45%
Jun 30, 202415928.23%44,686,1205.66%910.99%10926.74%3317.86%
Mar 31, 202412487.88%42,293,77126.24%961.79%86109.76%28154.55%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Fidelity Growth Compy Commingled Pl S2.20M3.72%-
Fidelity Growth Compy Commingled Pl O1.65M3.16%20.65K
Fidelity Growth Company Fund1.57M2.65%-
Vanguard Total Stock Mkt Idx Inv1.34M2.27%-
Vanguard US Total Market Shares ETF1.00M1.69%193.50K
iShares Russell 2000 ETF806.95K1.36%396.00
Fidelity Select Health Care699.39K1.18%9.70K
Fidelity Small Cap Growth695.07K1.17%10.78K
SPDR® S&P Biotech ETF634.92K1.07%822.00
Janus Henderson Global Life Sciences D527.16K0.89%-13.32K

Recent Insider Transactions


DateNameRoleActivityValue
May 01, 2025Meyer Andrew Hollman Chief Business OfficerSell$13.04K
May 01, 2025Meyer Andrew Hollman Chief Business OfficerSell$93.70K
Apr 21, 2025Meyer Andrew Hollman Chief Business OfficerSell$100.02K
Mar 06, 2025RA CAPITAL MANAGEMENT, L.P. Buy$11.45M
Mar 05, 2025RA CAPITAL MANAGEMENT, L.P. Buy$1.17M

Insider Transactions Trends


DateBuySell
2025 Q2-3
2025 Q1411
2024 Q4123
2024 Q3-33
2024 Q2-8

JANX Ownership FAQ


Who Owns Janux Therapeutics?

Janux Therapeutics shareholders are primarily institutional investors at 5.58%, followed by 6.59% insiders and 87.83% retail investors. The average institutional ownership in Janux Therapeutics's industry, Biotech Stocks , is 63.96%, which Janux Therapeutics falls below.

Who owns the most shares of Janux Therapeutics?

Janux Therapeutics’s largest shareholders are Ra capital management (11.19M shares, 18.11%), Fmr (8.67M shares, 15.87%), and Janus henderson group (3.56M shares, 6.52%). Together, they hold 40.50% of Janux Therapeutics’s total shares outstanding.

Does Blackrock own Janux Therapeutics?

Yes, BlackRock owns 4.78% of Janux Therapeutics, totaling 2.34M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 98.19M$. In the last quarter, BlackRock increased its holdings by 650.02K shares, a 38.37% change.

Who is Janux Therapeutics’s biggest shareholder by percentage of total assets invested?

Logos global management lp is Janux Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.83% of its assets in 1.25M Janux Therapeutics shares, valued at 66.92M$.

Who is the top mutual fund holder of Janux Therapeutics shares?

Fidelity Growth Compy Commingled Pl S is the top mutual fund holder of Janux Therapeutics shares, with 3.72% of its total shares outstanding invested in 2.2M Janux Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools